Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.81 |
| ▸ | PLK3 | Q9H4B4 | 15/20 | 0.81 |
| ▸ | PLK2 | Q9NYY3 | 13/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.80 |
| ▸ | CLK2 | P49760 | 3/20 | 0.80 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.80 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.80 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.80 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.80 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.80 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.80 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.80 |
| ▸ | PRKCG | P05129 | 2/20 | 0.80 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.80 |
| ▸ | NEK4 | P51957 | 2/20 | 0.80 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.80 |
| ▸ | BRD4 | O60885 | 6/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.75 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.75 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453446 | 1.00 | PLK1 (0.81) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL12825254 | 0.94 | PLK1 (0.84) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL20014306 | 0.94 | PLK1 (0.76) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL16971992 | 0.91 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL12323284 | 0.91 | PLK1 (0.85) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL29453442 | 0.91 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL376134 | 0.91 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL29922386 | 0.91 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL15257514 | 0.91 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL30325075 | 0.91 | PLK1 (0.86) | PLK1PLK3PLK2PRKD3CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10849980-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-9694084-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024319-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017007612-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| WO-2015117055-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | PLK1 2442/4885PLK3 3818/4885PLK2 3917/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | PLK1 1307/4885PLK3 3928/4885PLK2 2818/4885 |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | NFATC1, GZMB, ICOS | PLK1 2442/4885PLK3 3818/4885PLK2 3917/4885 |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | PLK1 2859/4885PLK3 2255/4885PLK2 2094/4885 |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | PLK1 1768/4885PLK3 4001/4885PLK2 3994/4885 |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, SMARCE1, MDM2 | PLK1 932/4885PLK3 3660/4885PLK2 1995/4885 |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-10849980-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | PLK1 838/4885PLK3 3346/4885PLK2 1729/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | PLK1 2709/4885PLK3 4748/4885PLK2 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.